The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies-A Pilot Study. — CFSMEATLAS
The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies-A Pilot Study.
Oesch-Régeni, Boglárka, Germann, Nicolas, Hafer, Georg et al. · Journal of clinical medicine · 2025 · DOI
Quick Summary
This small pilot study looked at seven ME/CFS patients who had high levels of specific antibodies (proteins the immune system makes) that may harm certain nerve and heart functions. The researchers gave these patients two types of blood-cleaning treatments—plasmapheresis (which filters antibodies out of blood) and immunoglobulins (healthy antibodies)—and tracked their symptoms and quality of life. They found that patients with higher levels of these harmful antibodies tended to report worse quality of life, and the treatments appeared to help reduce both the antibodies and improve how patients felt.
Why It Matters
This study provides preliminary evidence that a specific subset of ME/CFS patients may have measurable autoimmune mechanisms (antibody-mediated) that could explain their symptoms and potentially respond to targeted immunological treatments. If validated in larger studies, identifying and treating autoantibody-positive ME/CFS patients could offer a path toward personalized medicine and symptom improvement for a currently untreatable condition.
Observed Findings
Higher concentrations of β2-adrenergic receptor antibodies were associated with lower quality of life scores (−0.01 decrease in EQ-5D-5L index per 1 U/mL increase).
Higher concentrations of M3-muscarinic receptor antibodies showed stronger association with lower quality of life (−0.02 decrease in EQ-5D-5L index per 1 U/mL increase).
No significant associations were found between autoantibody titers and insomnia severity, depression, anxiety, or fatigue scores.
Patients tolerated four plasmapheresis sessions followed by low-dose IVIG therapy without reported serious adverse events.
Inferred Conclusions
Autoantibodies against β2-adrenergic and M3-muscarinic receptors show negative associations with quality of life in ME/CFS patients, suggesting a potential mechanistic role in disease burden.
Antibody-lowering therapies (plasmapheresis and IVIG) are feasible interventions in this patient population and warrant larger controlled trials to determine efficacy.
Careful patient selection based on autoantibody status may identify a more homogeneous ME/CFS subgroup responsive to immunological treatment.
Remaining Questions
Do plasmapheresis and IVIG actually improve symptoms and quality of life compared to placebo or standard care, or were improvements due to other factors?
How many ME/CFS patients overall have elevated β2-adrenergic and M3-muscarinic receptor autoantibodies, and is this a major pathogenic mechanism across the disease or limited to a small subgroup?
What This Study Does Not Prove
This small pilot study does not prove that plasmapheresis and IVIG are effective treatments for ME/CFS generally, nor does it establish that elevated autoantibodies directly cause ME/CFS symptoms (correlation vs. causation). The lack of a control group, small sample size, and lack of blinding mean these findings are preliminary feasibility data requiring substantial validation in larger, controlled trials before clinical recommendations can be made.
Which autoantibody levels or combinations predict treatment response, and what is the optimal dosing and duration of plasmapheresis and IVIG for this patient population?
Do improvements in autoantibody levels correlate with functional improvements in autonomic and neurological symptoms beyond quality of life questionnaires?